Biogen Data Complicates Quest to Slow Alzheimer’s Disease

Biogen Inc.’s experimental drug for Alzheimer’s disease failed to show a statistically significant cognitive benefit for patients on a closely watched dose, complicating the company’s quest to develop a treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.